Kim, Kevin B. et al
"Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma." Clinical Cancer Research
17.23
(2011):
7451-7461.
Web. 04 Mar. 2021.
